Location of Repository

Role of transcriptional and translational gene regulation in the mechanism of doxorubicin cardiotoxicity

By Amy Pointon

Abstract

Doxorubicin, one of the most widely used and effective anticancer drugs, is limited in its therapeutic use by cardiotoxicity. Multiple hypotheses have been advanced to explain the cardiotoxicity. In this project I utilised novel global genomic analysis of mRNA and miRNA transcription and mRNA translation to investigate the mechanism of doxorubicin cardiotoxicity in vivo. A comparator naphthoquinone was employed in parallel to specifically investigate the potential role of redox activity in the mechanism of cardiotoxicity. For both compounds mouse models were used where cardiac damage was characterised at several dose levels (acute and chronic repeat dosing for 7 weeks). A major transcriptionally and translationally affected pathway was the electron transport chain, this was further confirmed biochemically. These changes were reflected by a rapid loss of ATP and an associated increase in the AMP:ATP ratio and associated activation of AMPK indicating a change in cellular energy dynamics. In tandem mtDNA copy number and caspase 3 were rapidly increased. Comparison of all the data led to the hypothesis that the mechanism of doxorubicin toxicity was via interference with the electron transport chain, possibly through electron shuttling, leading to mitochondrial damage and activation of the intrinsic pathway of apoptosis. In further analysis miRNA alterations associated with the cardiotoxicity of both compounds were investigated. Several miRNAs appeared to be intrinsically involved and one of these, miR-181a was followed up in vitro in HL-1 cells and showed an association with susceptibility to doxorubicin cardiotoxicity. The findings provide a novel insight into doxorubicin cardiotoxicity, through the utilization of genomics and suggest the major mechanism of doxorubicin toxicity is via interference with the electron transport chain, and unrelated to the pharmacological action. These data offer the possibility of molecule alteration to retain the pharmacological profile without the associated cardiotoxicity

Publisher: University of Leicester
Year: 2009
OAI identifier: oai:lra.le.ac.uk:2381/8563

Suggested articles

Preview

Citations

  1. (2007). A cannabinoid anticancer quinone, HU-331, is more potent and less cardiotoxic than doxorubicin: a comparative in vivo study",
  2. (2007). A developmental view of microRNA function",
  3. (2006). A microRNA expression signature of human solid tumors defines cancer gene targets",
  4. (2007). A microRNA signature of hypoxia", Molecular and cellular biology,
  5. (2005). A mitochondrial paradigm of metabolic and degenerative diseases, aging, and cancer: a dawn for evolutionary medicine",
  6. (2006). A sensitive array for microRNA expression profiling (miChip) based on locked nucleic acids (LNA)",
  7. (2006). A signature pattern of stress-responsive microRNAs that can evoke cardiac hypertrophy and heart failure",
  8. (2004). A statistical framework for the design of microarray experiments and effective detection of differential gene expression",
  9. (2004). Activating transcription factor 4 is translationally regulated by hypoxic stress", Molecular and cellular biology,
  10. (2000). Acute doxorubicin cardiotoxicity involves cardiomyocyte apoptosis",
  11. (2005). Acute toxicity of doxorubicin on isolated perfused heart: response of kinases regulating energy supply", American journal of physiology.Heart and circulatory physiology,
  12. (1996). Adriamycin-induced DNA adducts inhibit the DNA interactions of transcription factors and RNA polymerase",
  13. (2007). Adriamycin-induced myocardial toxicity: new solutions for an old problem?",
  14. Adriamycin-induced oxidative mitochondrial cardiotoxicity", Cell biology and toxicology,
  15. (2008). Alpha-cardiac actin mutations produce atrial septal defects", Human molecular genetics,
  16. (2006). Alterations in myocardial energy metabolism induced by the anti-cancer drug doxorubicin", Comptes rendus biologies,
  17. (1999). American Society of Clinical Oncology clinical practice guidelines for the use of chemotherapy and radiotherapy protectants",
  18. (2007). AMP-activated protein kinase in the heart: role during health and disease",
  19. (2008). An improved spectrophotometric method for a more specific and accurate assay of mitochondrial complex III activity", Clinica chimica acta; international journal of clinical chemistry,
  20. (2006). Anthracycline cardiotoxicity",
  21. (2003). Anthracycline-induced suppression of GATA-4 transcription factor: implication in the regulation of cardiac myocyte apoptosis",
  22. (2004). Anthracyclines: molecular advances and pharmacologic developments in antitumor activity and cardiotoxicity",
  23. (1984). Antimitotics induce cardiolipin cluster formation. Possible role in mitochondrial enzyme inactivation",
  24. (2000). Antitumor properties of podophyllotoxin and related compounds",
  25. (2006). Apoptosis and anthracycline cardiotoxicity",
  26. (1996). Apoptosis in ischemic and reperfused rat myocardium",
  27. (2004). Apoptosis-A Brief Review",
  28. (2005). Apoptosis, pyroptosis, and necrosis: mechanistic description of dead and dying eukaryotic cells", Infection and immunity,
  29. (1972). Apoptosis: a basic biological phenomenon with wideranging implications in tissue kinetics",
  30. (2007). Apoptosis: a review of programmed cell death",
  31. (2009). Assembly of the oxidative phosphorylation system in humans: what we have learned by studying its defects",
  32. (2008). Association between mitochondrial DNA copy number, blood cell counts, and occupational benzene exposure", Environmental and molecular mutagenesis,
  33. (1995). ATP synthase from Saccharomyces cerevisiae",
  34. (2001). Attenuation of doxorubicin chronic toxicity in metallothioneinoverexpressing transgenic mouse heart",
  35. (2006). Autophagic programmed cell death by selective catalase degradation",
  36. (2002). Bcl-2 family members and functional electron transport chain regulate oxygen deprivation-induced cell death", Molecular and cellular biology,
  37. (2009). Beating behavior of primary neonatal cardiomyocytes and cardiac-differentiated P19.CL6 cells on different extracellular matrix components",
  38. (1984). Binding of adriamycin-Fe3+ complex to membrane phospholipids",
  39. (2004). Biomarkers of cardiac disease", Expert review of molecular diagnostics,
  40. (1971). Blood constituent changes in fasted swine",
  41. (2003). c-myc down-regulation induces apoptosis in human cancer cell lines exposed to RPR-115135 (C31H29NO4), a non-peptidomimetic farnesyltransferase inhibitor",
  42. (2003). Calcium and the heart: a question of life and death",
  43. (2002). Cardiac dysfunction in the trastuzumab clinical trials experience",
  44. (1996). Cardiac energy metabolism at several stages of adriamycin-induced heart failure in rats",
  45. (2000). Cardiac peroxynitrite formation and left ventricular dysfunction following doxorubicin treatment in mice",
  46. (2004). Cardiac physiology at the cellular level: use of cultured HL-1 cardiomyocytes for studies of cardiac muscle cell structure and function", American journal of physiology.Heart and circulatory physiology,
  47. (2008). Cardiac toxicity in breast cancer survivors: review of potential cardiac problems",
  48. (2008). Cardiac troponin is the most effective translational safety biomarker for myocardial injury in cardiotoxicity",
  49. (1997). Cardiac troponin T is a sensitive, specific biomarker of cardiac injury in laboratory animals",
  50. (2009). Cardiolipin remodeling in the heart",
  51. (2008). Cardiotoxic drugs: clinical monitoring and decision making",
  52. (2008). Cardiotoxicity of the new cancer therapeutics--mechanisms of, and approaches to, the problem", Drug discovery today,
  53. (2004). Carvedilol-mediated antioxidant protection against doxorubicin-induced cardiac mitochondrial toxicity", Toxicology and applied pharmacology,
  54. (2000). Cell cycle activation by c-myc in a burkitt lymphoma model cell line",
  55. (2004). Cellular internal ribosome entry segments: structures, trans-acting factors and regulation of gene expression",
  56. (2009). Chapter 1: Thesis Introduction Chapter 2: Materials and Methods Chapter 4: Evaluation of the Relative Cardiotoxicity of Doxorubicin and DMNQ in a Mouse Model Chapter 9: Thesis Discussion Al-Abd,
  57. (2003). Characterization of the human, mouse and rat PGC1 beta (peroxisome-proliferator-activated receptor-gamma co-activator 1 beta) gene in vitro and in vivo",
  58. (2007). Characterization of troponin responses in isoproterenol-induced cardiac injury in the Hanover Wistar rat", Toxicologic pathology,
  59. (2008). Circular reasoning: microRNAs and cell-cycle control", Trends in biochemical sciences,
  60. (2008). Circulating microRNAs as stable blood-based markers for cancer detection",
  61. (2003). Citrate synthase expression and enzyme activity after endurance training in cardiac and skeletal muscles",
  62. (2007). Clinical expression of Leber hereditary optic neuropathy is affected by the mitochondrial DNA-haplogroup background",
  63. (2006). Clinical implications of mitochondrial dysfunction",
  64. (2005). Combinatorial microRNA target predictions",
  65. (1992). Comparative study of doxorubicin, mitoxantrone, and epirubicin in combination with ICRF-187 (ADR-529) in a chronic cardiotoxicity animal model",
  66. (2007). Competing interactions between micro-RNAs determine neural progenitor survival and proliferation after ethanol exposure: evidence from an ex vivo model of the fetal cerebral cortical neuroepithelium",
  67. (2008). Complex I assay in mitochondrial preparations from CNS", Current protocols in toxicology,
  68. (2001). Concerted action of DT-diaphorase and superoxide dismutase in preventing redox cycling of naphthoquinones: an evaluation", Free radical research,
  69. (2002). Conditional mutation of the ErbB2 (HER2) receptor in cardiomyocytes leads to dilated cardiomyopathy",
  70. (2009). ConsensusPathDB--a database for integrating human functional interaction networks",
  71. (2008). Control of cardiac excitability by microRNAs",
  72. (2006). Control of mitochondrial gene expression in the aging rat myocardium",
  73. (2006). Control of translation and mRNA degradation by miRNAs and siRNAs",
  74. (2000). Corpse clearance defines the meaning of cell death",
  75. (2001). Cumulative and irreversible cardiac mitochondrial dysfunction induced by doxorubicin",
  76. (2004). Cyclooxygenase-2 inhibitor treatment improves left ventricular function and mortality in a murine model of doxorubicin-induced heart failure",
  77. (1993). Cytotoxicity of menadione and related quinones in freshly isolated rat hepatocytes: effects on thiol homeostasis and energy charge",
  78. (2004). Decrease in mitochondrial complex I activity in ischemic/reperfused rat heart: involvement of reactive oxygen species and cardiolipin",
  79. (2006). Deferiprone protects the isolated atria from cardiotoxicity induced by doxorubicin",
  80. (1984). Deficiencies and improvement of methemoglobin assay",
  81. (2008). Degradation of microRNAs by a family of exoribonucleases in Arabidopsis",
  82. (1997). Delayed administration of dexrazoxane provides cardioprotection for patients with advanced breast cancer treated with doxorubicin-containing therapy",
  83. (2006). Depletion of adenine nucleotide translocator protein in heart mitochondria from doxorubicin-treated rats--relevance for mitochondrial dysfunction",
  84. (2009). Detection of cancer with serum miRNAs on an oligonucleotide microarray",
  85. (2008). Detection of elevated levels of tumour-associated microRNAs in serum of patients with diffuse large B-cell lymphoma",
  86. (2005). Developmental biology: tiny brakes for a growing heart",
  87. (2003). Dexrazoxane does not protect against doxorubicin-induced damage in young rats", American journal of physiology.Heart and circulatory physiology,
  88. (2007). Dexrazoxane prevents doxorubicin-induced long-term cardiotoxicity and protects myocardial mitochondria from genetic and functional lesions in rats",
  89. (1995). Differential mechanisms of induction of the mitochondrial permeability transition by quinones of varying chemical reactivities", Toxicology and applied pharmacology,
  90. (2009). Differential regulation of Apak by various DNA damage signals", Molecular and cellular biochemistry,
  91. (1998). Disruption of the DT diaphorase (NQO1) gene in mice leads to increased menadione toxicity",
  92. (2005). Dissection of the mitochondrial import and assembly pathway for human Tom40",
  93. (2007). Distinct mechanisms of cardiomyocyte apoptosis induced by doxorubicin and hypoxia converge on mitochondria and are inhibited by Bcl-xL",
  94. (2006). DNA damage is an early event in doxorubicin-induced cardiac myocyte death", American journal of physiology.Heart and circulatory physiology,
  95. (2002). Doxorubicin administration by continuous infusion is not cardioprotective: the Dana-Farber 91-01 Acute Lymphoblastic Leukemia protocol",
  96. (1988). Doxorubicin cardiotoxicity may be caused by its metabolite, doxorubicinol",
  97. (2007). Doxorubicin degradation in cardiomyocytes",
  98. (2002). Doxorubicin treatment in vivo causes cytochrome C release and cardiomyocyte apoptosis, as well as increased mitochondrial efficiency, superoxide dismutase activity, and Bcl-2:Bax ratio",
  99. (2006). Doxorubicin-DNA adducts induce a non-topoisomerase II-mediated form of cell death",
  100. (1996). Doxorubicin-induced apoptosis in spontaneously hypertensive rats: differential effects in heart, kidney and intestine, and inhibition by ICRF-187",
  101. (2003). Doxorubicin-induced cardiac mitochondrionopathy",
  102. (2007). Doxorubicin-induced cardiomyopathy from the cardiotoxic mechanisms to management",
  103. (1989). DT-diaphorase-catalysed reduction of 1,4-naphthoquinone derivatives and glutathionyl-quinone conjugates. Effect of substituents on autoxidation rates",
  104. (2008). Dysregulation of microRNAs after myocardial infarction reveals a role of miR-29 in cardiac fibrosis",
  105. (1987). Effect of oxygen tension on the antitumor activity of mitomycin C assayed by human tumor clonogenic assay", The Japanese journal of surgery,
  106. (2005). Effect of pooling samples on the efficiency of comparative studies using microarrays",
  107. (2008). Emerging fundamental roles for non-coding RNA species in toxicology",
  108. (2008). Endoplasmic reticulum stress induces calcium-dependent permeability transition, mitochondrial outer membrane permeabilization and apoptosis",
  109. (2006). Enhancement of DMNQ-induced hepatocyte toxicity by cytochrome P450 inhibition", Toxicology and applied pharmacology,
  110. (2004). Essential role of GATA-4 in cell survival and drug-induced cardiotoxicity",
  111. (2009). Ethanol exposure induces differential microRNA and target gene expression and teratogenic effects which can be suppressed by folic acid supplementation", Human reproduction
  112. (2005). Evaluation of H-FABP as a marker of ongoing myocardial damage using hGH transgenic mice", Clinica chimica acta; international journal of clinical chemistry,
  113. (2003). Exosome release is regulated by a calciumdependent mechanism in K562 cells",
  114. (2007). Exosome-mediated transfer of mRNAs and microRNAs is a novel mechanism of genetic exchange between cells",
  115. (2006). Expression profiling reveals meiotic male germ cell mRNAs that are translationally up- and down-regulated",
  116. (2009). Extracardiac approaches to protecting the heart", European journal of cardio-thoracic surgery : official journal of the European Association for Cardio-thoracic Surgery,
  117. (1987). Formation and reduction of glutathione-protein mixed disulfides during oxidative stress. A study with isolated hepatocytes and menadione (2-methyl-1,4-naphthoquinone)",
  118. (2002). Frequent deletions and down-regulation of micro-
  119. (2007). Functional aspects of animal microRNAs",
  120. (2001). Functional disorders of the sympathetic nervous system in mice lacking the alpha 1B subunit (Cav 2.2) of N-type calcium channels",
  121. (2007). Genes and molecular pathways related to radioresistance of oral squamous cell carcinoma cells",
  122. (2004). Genes of glycolysis are ubiquitously overexpressed in 24 cancer classes",
  123. (2007). Genome-wide analysis of mRNA polysomal profiles with spotted DNA microarrays",
  124. (2006). Genomics of microRNA",
  125. (2006). Global alterations in mRNA polysomal recruitment in a cell model of colorectal cancer progression to metastasis",
  126. (2008). Glucose phosphorylation and mitochondrial binding are required for the protective effects of hexokinases I and II", Molecular and cellular biology,
  127. (2009). Granulocyte colonystimulating factor protects cardiac mitochondria in the early phase of cardiac injury", American journal of physiology.Heart and circulatory physiology,
  128. (2001). Healing the heart with ventricular assist device therapy: mechanisms of cardiac recovery", The Annals of thoracic surgery,
  129. (2008). Heart failure: targeting transcriptional and post-transcriptional control mechanisms of hypertrophy for treatment",
  130. (2008). Heart mitochondria: gates of life and death",
  131. (2005). Hepatic gene expression in protoporphyic Fech mice is associated with cholestatic injury but not a marked depletion of the heme regulatory pool", The American journal of pathology,
  132. (2009). HIF-1alpha modulation by topoisomerase inhibitors in non-small cell lung cancer cell lines",
  133. (1998). HL-1 cells: a cardiac muscle cell line that contracts and retains phenotypic characteristics of the adult cardiomyocyte",
  134. (2005). How well does B-type natriuretic peptide predict death and cardiac events in patients with heart failure: systematic review",
  135. (2007). HU-331, a novel cannabinoid-based anticancer topoisomerase II inhibitor",
  136. (2000). Human carbonyl reductase overexpression in the heart advances the development of doxorubicin-induced cardiotoxicity in transgenic mice",
  137. (2007). Hyperglycemia decreases mitochondrial function: the regulatory role of mitochondrial biogenesis", Toxicology and applied pharmacology,
  138. (2009). IEX-1 targets mitochondrial F1Fo-ATPase inhibitor for degradation", Cell death and differentiation,
  139. (2008). Implication of microRNAs in the cardiovascular system", Current opinion in pharmacology,
  140. (2009). In vitro pharmacologic testing using human induced pluripotent stem cell-derived cardiomyocytes", Biochemical and biophysical research communications,
  141. (2002). In vivo and in organello assessment of OXPHOS activities",
  142. (2008). In vivo assessment of mitochondrial toxicity",
  143. (1998). In vivo prevention of adriamycin cardiotoxicity by cyclosporin A or FK506",
  144. (2006). Increase in mitochondrial DNA quantity and impairment of oxidative phosphorylation in bovine fibroblast cells treated with ethidium bromide for 15 passages in culture",
  145. (2000). Increase in the adenine nucleotide translocase content of duckling subsarcolemmal mitochondria during cold acclimation",
  146. (1998). Induction of antioxidants by adriamycin in mouse heart",
  147. (2007). Induction of microRNAome deregulation in rat liver by long-term tamoxifen exposure",
  148. (2004). Inherent redox properties of diesel exhaust particles: catalysis of the generation of reactive oxygen species by biological reductants", Toxicological sciences : an official journal of the
  149. (1990). Inhibition of transcription by adriamycin is a consequence of the loss of negative superhelicity in DNA mediated by topoisomerase II", Molecular and cellular biochemistry,
  150. (1985). Interaction of menadione (2-methyl-1,4-naphthoquinone) with glutathione",
  151. (1994). Interference by doxorubicin with DNA unwinding in MCF-7 breast tumor cells",
  152. (2001). Iron on the brain",
  153. (2008). Large-scale chemical dissection of mitochondrial function",
  154. (1999). Lipid peroxidation-DNA damage by malondialdehyde",
  155. (2009). Many roads to maturity: microRNA biogenesis pathways and their regulation",
  156. (2008). MAPK signalling in cardiovascular health and disease: molecular mechanisms and therapeutic targets", Clinical science (London,
  157. (1986). Mechanism of inhibition of mitochondrial enzymatic complex I-III by adriamycin derivatives",
  158. (1998). Mechanism of inhibition of mitochondrial respiratory complex I by 6-hydroxydopamine and its prevention by desferrioxamine",
  159. (2006). Messenger RNAs under differential translational control in Ki-ras-transformed cells",
  160. (2007). Methamphetamine and cardiovascular pathology: a review of the evidence",
  161. (2000). Methamphetamine induces an increase in cell size and reorganization of myofibrils in cultured adult rat cardiomyocytes",
  162. (2005). Methamphetamine-induced inhibition of mitochondrial complex II: roles of glutamate and peroxynitrite",
  163. (2007). Methods to analyze microRNA-mediated control of mRNA translation",
  164. (2007). Micro-RNA speciation in fetal, adult and Alzheimer's disease hippocampus",
  165. (2008). MicroRNA and cardiac pathologies",
  166. (2008). MicroRNA epigenetic alterations: predicting biomarkers and therapeutic targets in human diseases",
  167. (2007). microRNA expression in the prefrontal cortex of individuals with schizophrenia and schizoaffective disorder",
  168. (2005). MicroRNA expression profiles classify human cancers",
  169. (2007). MicroRNA may have macro effect on sudden death",
  170. (2007). MicroRNA miR-133 represses HERG K+ channel expression contributing to QT prolongation in diabetic hearts",
  171. (2009). MicroRNA regulation of cardiovascular development",
  172. (2009). MicroRNA-195 suppresses tumorigenicity and regulates G1/S transition of human hepatocellular carcinoma cells",
  173. (2008). MicroRNA-21 contributes to myocardial disease by stimulating MAP kinase signalling in fibroblasts",
  174. (2008). MicroRNA-26a targets the histone methyltransferase Enhancer of Zeste homolog 2 during myogenesis",
  175. (2008). MicroRNA: an Emerging Therapeutic Target and Intervention Tool",
  176. (2009). MicroRNAs and cardiac pathology",
  177. (2009). microRNAs and muscle disorders",
  178. (2009). MicroRNAs as a therapeutic target for cardiovascular diseases",
  179. (2006). MicroRNAs direct rapid deadenylation of mRNA",
  180. (2007). MicroRNAs in the human heart: a clue to fetal gene reprogramming in heart failure",
  181. (2007). microRNAs join the p53 network--another piece in the tumour-suppression puzzle",
  182. (2007). MicroRNAs: powerful new regulators of heart disease and provocative therapeutic targets",
  183. (2009). MicroRNAs: regulating a change of heart",
  184. (2006). MicroRNAs: regulators of gene expression and cell differentiation",
  185. (2008). MicroRNAs: role in cardiovascular biology and disease",
  186. (1989). Microsomal lipid peroxidation induced by adriamycin, epirubicin, daunorubicin and mitoxantrone: a comparative study", Cancer chemotherapy and pharmacology,
  187. (2009). miR-15a and miR-16 are implicated in cell cycle regulation in a Rb-dependent manner and are frequently deleted or down-regulated in non-small cell lung cancer",
  188. (2009). miR-17 and miR-20a temper an E2F1-induced G1 checkpoint to regulate cell cycle progression",
  189. (2007). miR-181a is an intrinsic modulator of T cell sensitivity and selection",
  190. (2009). miR-29 miRNAs activate p53 by targeting p85 alpha and CDC42",
  191. (2007). miRNAs get an early start on translational silencing",
  192. (2004). miRNAs on the move: miRNA biogenesis and the RNAi machinery", Current opinion in cell biology,
  193. (2005). miRNAs, cancer, and stem cell division",
  194. (2000). Mitochondria and cell death",
  195. (2007). Mitochondria on the move", Trends in cell biology,
  196. (2005). Mitochondrial complex I activity is impaired during HIV1-induced T-cell apoptosis", Cell death and differentiation,
  197. (2009). Mitochondrial DNA is a direct target of anti-cancer anthracycline drugs", Biochemical and biophysical research communications,
  198. (2002). Mitochondrial DNA repair of oxidative damage in mammalian cells",
  199. (2008). Mitochondrial drugs", Current opinion in chemical biology,
  200. (2002). Mitochondrial dynamics and division in budding yeast", Trends in cell biology,
  201. (2000). Mitochondrial dysfunction in heart failure: potential for therapeutic interventions?",
  202. (2005). Mitochondrial energy metabolism in heart failure: a question of balance",
  203. (2007). Mitochondrial medicine: pharmacological targeting of mitochondria in disease",
  204. (2008). Mitochondrial off targets of drug therapy", Trends in pharmacological sciences,
  205. (2001). Mitochondrial permeability transition and oxidative stress",
  206. (2000). Mitochondrial targets of drug toxicity",
  207. (2001). Mitochondrial transcription factor A and respiratory complex IV increase in response to exercise training in humans", Pflugers Archiv : European journal of physiology,
  208. (2004). Mitochondrial transcription factor A regulates mtDNA copy number in mammals", Human molecular genetics,
  209. (2004). Mobilization of adenine nucleotide translocators as molecular bases of the biochemical threshold effect observed in mitochondrial diseases",
  210. (2007). Modification of miR gene expression pattern in human colon cancer cells following exposure to 5-fluorouracil in vitro",
  211. (1991). Modifications of cardiac contractility by redox cycling alkylating and mixed redox cycling/alkylating quinones",
  212. (2005). Molecular mechanism and regulation of autophagy",
  213. (1997). Molecular mechanisms of doxorubicin-induced cardiomyopathy. Selective suppression of Reiske iron-sulfur protein, ADP/ATP translocase, and phosphofructokinase genes is associated with ATP depletion in rat cardiomyocytes",
  214. (1991). Molecular mechanisms of quinone cytotoxicity",
  215. (2007). Molecular medicine: microRNAs and the tell-tale heart",
  216. (2007). Monitoring left ventricular function in adults receiving anthracycline-containing chemotherapy",
  217. (2009). Morphological alterations induced by doxorubicin on H9c2 myoblasts: nuclear, mitochondrial, and cytoskeletal targets", Cell biology and toxicology,
  218. (2009). Morphological dynamics of mitochondria--a special emphasis on cardiac muscle cells",
  219. (2007). Moving mitochondria: establishing distribution of an essential organelle",
  220. (2006). mTOR, translation initiation and cancer",
  221. (1995). Multiple essential functions of neuregulin in development",
  222. (2003). Multiple organ pathology, metabolic abnormalities and impaired homeostasis of reactive oxygen species in Epas1-/- mice",
  223. (1996). Nature of inhibition of mitochondrial respiratory complex I by 6-Hydroxydopamine",
  224. (2006). New insights into doxorubicin-induced cardiotoxicity: the critical role of cellular energetics",
  225. (2008). New insights into mechanisms of statin-associated myotoxicity", Current opinion in pharmacology,
  226. (2009). Novel genomic methods for drug discovery and mechanism-based toxicological assessment",
  227. (2000). NRH:quinone oxidoreductase2 (NQO2)",
  228. (2008). Nuclear control of respiratory chain expression by nuclear respiratory factors and PGC-1-related coactivator",
  229. (2006). Nuclear control of respiratory gene expression in mammalian cells",
  230. (1940). Oral and parental toxicity of vitamin K1, phthiocol and 2-methyl-1, 4, naphthoquinone", Proceedings-society for experimental biology and medicine,
  231. (2008). Orientation of the calcium channel beta relative to the alpha(1)2.2 subunit is critical for its regulation of channel activity",
  232. (1997). Overexpression of metallothionein in the heart of transgenic mice suppresses doxorubicin cardiotoxicity",
  233. (1999). Oxidative phosphorylation at the fin de siecle",
  234. (1985). Oxygen dependence and subcellular partitioning of hepatic menadione-mediated oxygen uptake. Studies with isolated hepatocytes, mitochondria, and microsomes from rat liver in an oxystat system",
  235. (2006). Oxygen sensing by mitochondria at complex III: the paradox of increased reactive oxygen species during hypoxia",
  236. (2008). Oxygen tension during in vitro culture of bovine embryos: effect in production and expression of genes related to oxidative stress",
  237. (2003). Oxygen-insensitive nitroreductases NfsA and NfsB of Escherichia coli function under anaerobic conditions as lawsone-dependent Azo reductases",
  238. (2005). Pathways to the analysis of microarray data",
  239. (2003). Peroxisome proliferator-activated receptor-gamma coactivator 1 alpha (PGC-1 alpha): transcriptional coactivator and metabolic regulator",
  240. Persistent alterations to the gene expression profile of the heart subsequent to chronic Doxorubicin treatment",
  241. (2006). PGC-1alpha: a key regulator of energy metabolism",
  242. (1999). Pharmacokinetic interactions of paclitaxel, docetaxel and their vehicles with doxorubicin",
  243. (2002). Pharmacokinetic-pharmacodynamic relationships of the anthracycline anticancer drugs",
  244. (1999). Phase I and pharmacokinetic study of the topoisomerase II catalytic inhibitor fostriecin",
  245. (1999). Piceatannol, a stilbene phytochemical, inhibits mitochondrial F0F1-ATPase activity by targeting the F1 complex", Biochemical and biophysical research communications,
  246. (2009). Pivotal role for two electron reduction in 2,3-dimethoxy-1,4-naphthoquinone and 2-methyl-1,4-naphthoquinone metabolism and kinetics in vivo that prevents liver redox stress", Chemical research in toxicology,
  247. (2003). Potent metalloporphyrin peroxynitrite decomposition catalyst protects against the development of doxorubicin-induced cardiac dysfunction”,
  248. (2007). Preclinical assessment of anthracycline cardiotoxicity in laboratory animals: predictiveness and pitfalls", Cell biology and toxicology,
  249. (2007). Preconditioning and postconditioning: the essential role of the mitochondrial permeability transition pore",
  250. (2009). Predicting microRNA targets in time-series microarray experiments via functional data analysis",
  251. (1981). Prevention of doxorubicin cardiac toxicity in the mouse by N-acetylcysteine",
  252. (2004). Processes underlying the upregulation of Tom proteins in S. cerevisiae mitochondria depleted of the VDAC channel",
  253. (1985). Quinones as mutagens, carcinogens, and anticancer agents: introduction and overview",
  254. (2006). Radiation-induced changes in gene expression involve recruitment of existing messenger RNAs to and away from polysomes",
  255. (1998). Randomized prospective clinical trial of high-dose epirubicin and dexrazoxane in patients with advanced breast cancer and soft tissue sarcomas",
  256. (2000). Reactive oxygen species in cell signaling", American journal of physiology.Lung cellular and molecular physiology,
  257. (2009). Reactive oxygen species-independent apoptosis in doxorubicin-treated H9c2 cardiomyocytes: role for heme oxygenase-1 downmodulation",
  258. (2009). Reciprocal regulation of myocardial microRNAs and messenger RNA in human cardiomyopathy and reversal of the microRNA signature by biomechanical support",
  259. (1988). Redox cycling and sulphydryl arylation; their relative importance in the mechanism of quinone cytotoxicity to isolated hepatocytes",
  260. (1986). Redox cycling of anthracyclines by cardiac mitochondria. II. Formation of superoxide anion, hydrogen peroxide, and hydroxyl radical",
  261. (2005). Regulation of cap-dependent translation by eIF4E inhibitory proteins",
  262. (2003). Regulation of mRNA translation by 5'- and 3'-UTRbinding factors", Trends in biochemical sciences,
  263. (1997). Regulation of myocardial carbohydrate metabolism under normal and ischaemic conditions. Potential for pharmacological interventions",
  264. (1980). Relationship of the single-electron reduction potential of quinones to their reduction by flavoproteins",
  265. (1994). Reperfusion injury induces apoptosis in rabbit cardiomyocytes",
  266. (2007). Repression of protein synthesis by miRNAs: how many mechanisms?", Trends in cell biology,
  267. (2006). Restoring depressed HERG K+ channel function as a mechanism for insulin treatment of abnormal QT prolongation and associated arrhythmias in diabetic rabbits", American journal of physiology.Heart and circulatory physiology,
  268. (2006). Reversible inhibition of mitochondrial complex I activity following chronic dopaminergic glutathione depletion in vitro: implications for Parkinson's disease",
  269. (2008). Right into the heart of microRNA-133a",
  270. (2004). Role of apoptosis in remodeling after myocardial infarction",
  271. (1999). Role of iron in anthracycline cardiotoxicity: new tunes for an old song?",
  272. (2009). Role of microRNAs in cardiac hypertrophy and heart failure",
  273. (2000). Role of quinones in toxicology",
  274. (1994). Role of thiol homeostasis and adenine nucleotide metabolism in the protective effects of fructose in quinone-induced cytotoxicity in rat hepatocytes",
  275. (2005). Rotenone model of Parkinson disease: multiple brain mitochondria dysfunctions after short term systemic rotenone intoxication",
  276. (2009). Sensitive high performance liquid chromatographic assay for assessment of doxorubicin pharmacokinetics in mouse plasma and tissues",
  277. (2007). Serum cardiac markers in patients with acute myocardial infarction: oxidative stress, C-reactive protein and N-terminal probrain natriuretic Peptide",
  278. (2006). Serum chemical biomarkers of cardiac injury for nonclinical safety testing",
  279. (2004). Serum troponins as biomarkers of drug-induced cardiac toxicity", Toxicologic pathology,
  280. (2006). Short RNAs repress translation after initiation in mammalian cells",
  281. (2000). Signaling and expression for mitochondrial membrane proteins during left ventricular remodeling and contractile failure after myocardial infarction",
  282. (2004). Significance of respirasomes for the assembly/stability of human respiratory chain complex I",
  283. (2003). Silent cleanup of very early apoptotic cells by macrophages",
  284. (2009). Specialized piRNA pathways act in germline and somatic tissues of the Drosophila ovary",
  285. (2007). STIM2 is a feedback regulator that stabilizes basal cytosolic and endoplasmic reticulum Ca2+ levels",
  286. (1990). Structure of the adriamycin-cardiolipin complex. Role in mitochondrial toxicity",
  287. (1967). Studies on cytochrome oxidase. 3. Ligand reactions and Schiff base formation of heme a",
  288. (1983). Substituted 1,4-naphthoquinones vs. the ascitic sarcoma 180 of mice",
  289. (2008). Succinate ameliorates energy deficits and prevents dysfunction of complex I in injured renal proximal tubular cells",
  290. (1996). Suppression of doxorubicin cardiotoxicity by overexpression of catalase in the heart of transgenic mice",
  291. (2008). Tackling heart failure in the twenty-first century",
  292. (2008). Taking microRNAs to heart", Trends in molecular medicine,
  293. (2007). Targeting antioxidants to mitochondria and cardiovascular
  294. (2004). Tcap gene mutations in hypertrophic cardiomyopathy and dilated cardiomyopathy",
  295. (2008). TCAP knockdown by RNA interference inhibits myoblast differentiation in cultured skeletal muscle cells",
  296. (2005). The actin cytoskeleton in ageing and apoptosis",
  297. (1992). The anthracyclines: will we ever find a better doxorubicin?",
  298. (2000). The coactivator PGC-1 cooperates with peroxisome proliferator-activated receptor alpha in transcriptional control of nuclear genes encoding mitochondrial fatty acid oxidation enzymes", Molecular and cellular biology,
  299. (2004). The effect of dexrazoxane on myocardial injury in doxorubicin-treated children with acute lymphoblastic leukemia", The New England journal of medicine,
  300. (2008). The impact of microRNAs on protein output",
  301. (2005). The implications of structured 5' untranslated regions on translation and disease",
  302. (2005). The increase in mitochondrial DNA copy number in the tissues of gamma-irradiated mice",
  303. (2008). The long-term prognostic value of multiple biomarkers following a myocardial infarction",
  304. (2002). The metabolism and toxicity of quinones, quinonimines, quinone methides, and quinone-thioethers",
  305. (2006). The microRNA miR-181 targets the homeobox protein Hox-A11 during mammalian myoblast differentiation",
  306. (2009). The miR-18a* microRNA functions as a potential tumor suppressor by targeting on K-Ras",
  307. (2004). The mitochondrial transporter family (SLC25): physiological and pathological implications", Pflugers Archiv :
  308. (2009). The molecular composition of the mitochondrial permeability transition pore",
  309. (2007). The muscle-specific microRNAs miR-1 and miR-133 produce opposing effects on apoptosis by targeting HSP60, HSP70 and caspase-9 in cardiomyocytes",
  310. (2004). The problem of interlab variation in methods for mitochondrial disease diagnosis: enzymatic measurement of respiratory chain complexes",
  311. (2006). The role of iron regulatory proteins in mammalian iron homeostasis and disease",
  312. (2007). The role of mitochondria in pharmacotoxicology: a reevaluation of an old, newly emerging topic", American journal of physiology.Cell physiology,
  313. (2000). The role of NAD(P)H oxidoreductase (DT-Diaphorase) in the bioactivation of quinone-containing antitumor agents: a review",
  314. (2008). The search for new cardiovascular biomarkers",
  315. (2007). The significance of mitochondrial toxicity testing in drug development", Drug discovery today,
  316. (2008). Therapy Insight: anthracyclines and trastuzumab--the optimal management of cardiotoxic side effects",
  317. (2003). Time-dependent and tissue-specific accumulation of mtDNA and respiratory chain defects in chronic doxorubicin cardiomyopathy",
  318. (2009). Tiny RNAs associated with transcription start sites in animals",
  319. (2008). Topoisomerase II inhibition involves characteristic chromosomal expression patterns",
  320. (2008). Toward microRNA-based therapeutics for heart disease: the sense in antisense",
  321. (2004). Toxicology of antisense therapeutics",
  322. (2004). Transcription and processing of human microRNA precursors",
  323. (2006). Transcriptional analysis of doxorubicin-induced cardiotoxicity", American journal of physiology.Heart and circulatory physiology,
  324. (2004). Transcriptional regulatory circuits controlling mitochondrial biogenesis and function",
  325. (2006). Translational control of gene expression during hypoxia",
  326. (2009). Trastuzumab versus lapatinib: The cardiac side of the story", Cancer treatment reviews,
  327. (2005). TRBP recruits the Dicer complex to Ago2 for microRNA processing and gene silencing",
  328. (2003). VDAC2 inhibits BAK activation and mitochondrial apoptosis",
  329. (2007). Voltage-dependent anion channels are dispensable for mitochondrial-dependent cell death",
  330. (2008). What is principal component analysis?",
  331. (2008). Widespread changes in protein synthesis induced by microRNAs",
  332. (2009). With great power comes great responsibility: using mouse genetics to study cardiac hypertrophy and failure",

To submit an update or takedown request for this paper, please submit an Update/Correction/Removal Request.